AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AMGEN INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$424.94−7.55 (-1.75%)
Close on Oct 19, 2026
- Market cap
- $231.17B
- P/E (TTM)
- 26.4
- Dividend yield
- 2.27%
Amgen statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Amgen | Industry median |
|---|---|---|
| Market Cap | $229.74B | $197.05M |
| Enterprise Value | $273.05B | $106.56M |
| PE Ratio | 26.39 | 20.52 |
| PS Ratio | 6.03 | 3.93 |
| PB Ratio | 19.66 | 2.14 |
| P/FCF Ratio | 22.58 | 18.25 |
| P/OCF Ratio | 18.41 | 13.78 |
Enterprise value
| Measure | Amgen | Industry median |
|---|---|---|
| EV / Sales | 7.17 | 2.69 |
| EV / EBITDA | 19.33 | 14.86 |
| EV / EBIT | 23.90 | 19.00 |
| EV / FCF | 26.84 | 21.02 |
Income (trailing twelve months)
| Measure | Amgen | Industry median |
|---|---|---|
| Revenue | $38.10B | $57.94M |
| Gross Profit | $26.48B | $90.47M |
| Operating Income | $11.43B | -$21.44M |
| Pretax Income | $10.29B | -$14.45M |
| Net Income | $8.74B | -$22.46M |
| EBITDA | $14.13B | -$16.91M |
| EPS (Diluted) | $16.10 | -$0.83 |
Margins
| Measure | Amgen | Industry median |
|---|---|---|
| Gross Margin | 69.5% | 52.3% |
| Operating Margin | 30.0% | -44.5% |
| Pretax Margin | 27.0% | -13.0% |
| Profit Margin | 23.0% | -39.2% |
| EBITDA Margin | 37.1% | -31.3% |
| FCF Margin | 26.7% | -8.85% |
Returns
| Measure | Amgen | Industry median |
|---|---|---|
| Return on Equity (ROE) | 91.5% | -53.1% |
| Return on Assets (ROA) | 9.53% | -41.0% |
| Return on Invested Capital (ROIC) | 17.6% | -32.0% |
| Return on Capital Employed (ROCE) | 16.3% | -37.8% |
Growth
| Measure | Amgen | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 9.10% | 6.01% |
| Net Income Growth (YoY) | 32.1% | -37.7% |
| EPS Growth (YoY) | 31.6% | -29.2% |
| FCF Growth (YoY) | -4.05% | 2.34% |
| Revenue Growth (3Y CAGR) | 11.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 7.65% | 6.42% |
| EPS Growth (3Y CAGR) | 5.52% | -0.17% |
| EPS Growth (5Y CAGR) | 2.94% | 3.77% |
Balance sheet
| Measure | Amgen | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $13.99B | $62.42M |
| Total Debt | $57.30B | $120.13M |
| Net Cash (Debt) | -$43.32B | $15.68M |
| Net Cash Per Share | -$80.12 | $0.65 |
| Equity (Book Value) | $11.69B | $48.79M |
| Book Value Per Share | $21.62 | $1.36 |
| Tangible Book Value | -$27.47B | $23.06M |
| Working Capital | $9.46B | $75.77M |
Financial position
| Measure | Amgen | Industry median |
|---|---|---|
| Current Ratio | 1.37 | 3.30 |
| Quick Ratio | 0.95 | 2.39 |
| Debt / Equity | 4.90 | 0.51 |
| Debt / EBITDA | 4.06 | 3.35 |
| Debt / FCF | 5.63 | 5.05 |
| Net Debt / EBITDA | 3.07 | 2.22 |
| Interest Coverage | 4.28 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Amgen | Industry median |
|---|---|---|
| Operating Cash Flow | $12.48B | -$12.35M |
| Capital Expenditures | -$2.30B | -$1.06M |
| Free Cash Flow | $10.18B | -$20.28M |
| FCF Per Share | $18.82 | -$0.41 |
Efficiency
| Measure | Amgen | Industry median |
|---|---|---|
| Asset Turnover | 0.42 | 0.38 |
| Inventory Turnover | 1.81 | 2.67 |
| Revenue Per Employee | $1.21M | $398.96K |
| Profits Per Employee | $277.56K | -$732.08K |
| Employee Count | 31,500 | 73 |
Dividends and yields
| Measure | Amgen | Industry median |
|---|---|---|
| Earnings Yield | 3.81% | -21.2% |
| FCF Yield | 4.43% | -7.64% |
| Dividend Yield | 2.27% | 1.83% |
| Shareholder Yield | 2.27% | 0.00% |
| Dividend Per Share | $9.66 | $0.83 |
| Dividend Growth (YoY) | 5.81% | 2.37% |
| Years of Dividend Growth | 9 | 0 |
| Payout Ratio | 60.4% | 47.7% |
| FCF Payout Ratio | 51.9% | 51.6% |
Shares
| Measure | Amgen | Industry median |
|---|---|---|
| Shares Outstanding | 540,632,000 | 59,128,900 |
| Shares Change (YoY) | 0.32% | 11.1% |
| Shares Change (QoQ) | 0.17% | 0.54% |
| Float | 539,504,000 | 48,744,500 |
| Shares Held by Insiders | 0.21% | 11.8% |
| Shares Held by Institutions | 82.7% | 59.4% |
Taxes
| Measure | Amgen | Industry median |
|---|---|---|
| Income Tax | $1.54B | $91.50K |
| Effective Tax Rate | 15.0% | 20.6% |
Scores
| Measure | Amgen | Industry median |
|---|---|---|
| Graham Number | $88.50 | $17.36 |
| Graham Upside | -79.2% | -45.5% |
| Altman Z-Score | 2.23 | 0.10 |
| Piotroski F-Score | 7 | 4 |
| Beneish M-Score | -2.26 | -2.62 |
Calculated by StockData from Amgen's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.